Home » Stocks » HOWL

Werewolf Therapeutics, Inc. (HOWL)

Stock Price: $19.45 USD 1.14 (6.23%)
Updated Jul 26, 2021 4:00 PM EDT - Market closed
Market Cap 535.38M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 27.53M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 26
Last Price $19.45
Previous Close $18.31
Change ($) 1.14
Change (%) 6.23%
Day's Open 18.42
Day's Range 18.42 - 19.57
Day's Volume 48,717
52-Week Range 11.23 - 23.99

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

CAMBRIDGE, Mass., June 24, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc., an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to ...

1 month ago - GlobeNewsWire

- Recently completed upsized initial public offering raising $120.0 million in gross proceeds - - Recently completed upsized initial public offering raising $120.0 million in gross proceeds -

1 month ago - GlobeNewsWire

CAMBRIDGE, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics ...

1 month ago - GlobeNewsWire

Werewolf Therapeutics (HOWL) stock is doing incredibly well for its first day of trading on the Nasdaq following its IPO. The post Werewolf Therapeutics IPO: HOWL Stock Comes Out Howling on First Day of...

2 months ago - InvestorPlace

CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (NASDAQ: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutic...

2 months ago - GlobeNewsWire

After banking $72 million at the start of the year, Werewolf Therapeutics now wants an IPO.

3 months ago - FierceBiotech

Werewolf Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

3 months ago - SEC

About HOWL

Werewolf Therapeutics is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. We are leveraging our proprietary PREDATORTM platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our molecules, which we refer to as INDUKINETM molecules, are intended to selectively target the tumor microenvironment, ... [Read more...]

Industry
Biotechnology
IPO Date
Apr 30, 2021
CEO
Daniel J. Hicklin, Ph.D.
Employees
28
Stock Exchange
NASDAQ
Ticker Symbol
HOWL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for HOWL is 26.50, which is an increase of 36.25% from the latest price.

Price Target
$26.50
(36.25% upside)